Bokf Na Acquires New Shares in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Bokf Na bought a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 27,212 shares of the company’s stock, valued at approximately $562,000.

Other hedge funds have also added to or reduced their stakes in the company. Hennion & Walsh Asset Management Inc. grew its stake in Pacira BioSciences by 18.1% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 56,385 shares of the company’s stock valued at $1,062,000 after acquiring an additional 8,636 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in Pacira BioSciences by 495.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after purchasing an additional 2,749 shares in the last quarter. Gagnon Securities LLC boosted its holdings in Pacira BioSciences by 4.8% in the 4th quarter. Gagnon Securities LLC now owns 321,743 shares of the company’s stock valued at $6,062,000 after purchasing an additional 14,800 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Pacira BioSciences by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock valued at $184,000 after purchasing an additional 918 shares in the last quarter. Finally, Caitlin John LLC increased its holdings in shares of Pacira BioSciences by 1,850.0% in the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock worth $35,000 after purchasing an additional 1,776 shares during the period. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Price Performance

PCRX stock opened at $25.12 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The firm has a market cap of $1.16 billion, a P/E ratio of -12.37 and a beta of 0.56. The firm’s fifty day moving average is $24.73 and its 200 day moving average is $22.10. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $31.67.

Analysts Set New Price Targets

Several research firms recently commented on PCRX. Barclays boosted their target price on Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. HC Wainwright boosted their price objective on Pacira BioSciences from $48.00 to $65.00 and gave the stock a “buy” rating in a report on Tuesday, April 8th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $18.00 target price on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Needham & Company LLC cut their price target on shares of Pacira BioSciences from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Friday. Finally, Truist Financial upgraded shares of Pacira BioSciences from a “sell” rating to a “hold” rating and raised their price objective for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Pacira BioSciences has a consensus rating of “Hold” and an average price target of $26.44.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.